Baird last night initiated coverage of Omada Health (OMDA) with a Neutral rating and $24 price target The company’s platform addresses important chronic conditions that have wide prevalence across the population, the analyst tells investors in a research note. However, Baird views the uncertain macro backdrop, Omada’s relatively high customer concentration, and its limited profitability as creating heightened risk for the shares.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OMDA:
- Omada Health initiated with a Neutral at Baird
- Omada Health announce research on cost savings of virtual physical therapy
- Five new option listings and one option delisting on August 22nd
- Omada Health price target raised to $28 from $27 at Canaccord
- Omada Health price target raised to $24 from $21 at Barclays